Convergent Therapeutics
Updated: December 25, 2025
Founder Philip Kantoff
Country: USA | Funding: $130M (+)
Founded: 2021
Website: https://convergentrx.com
Convergent Therapeutics develops radiopharmaceuticals for the treatment of prostate cancer. These are radioantibodies that deliver alpha-emitting agents, which carry the radioactive payload directly to the cancer cells, making radiation therapy more targeted and effective. The short-acting nature of these alpha-emitting agents minimizes radiation exposure to healthy adjacent cells and tissue. Each radioantibody is created through careful selection of an antibody with high affinity for a specific cancer target. The company's flagship drug, CONV01-α, is a radioantibody labeled with actinium-225, with proven efficacy and safety in multiple Phase 1/2 trials in prostate cancer patients.
Founded: 2021
Website: https://convergentrx.com
Convergent Therapeutics develops radiopharmaceuticals for the treatment of prostate cancer. These are radioantibodies that deliver alpha-emitting agents, which carry the radioactive payload directly to the cancer cells, making radiation therapy more targeted and effective. The short-acting nature of these alpha-emitting agents minimizes radiation exposure to healthy adjacent cells and tissue. Each radioantibody is created through careful selection of an antibody with high affinity for a specific cancer target. The company's flagship drug, CONV01-α, is a radioantibody labeled with actinium-225, with proven efficacy and safety in multiple Phase 1/2 trials in prostate cancer patients.
